The stock's rise snapped a four-day losing streak.
Fintel on MSN12h
Stifel Downgrades Vertex (VERX)Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.
Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.
BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...
DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.
We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...
Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...
In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.
About the company: SurgeGraph Vertex is an AI writing tool with a mission to help users grow their website traffic through ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...
About the company: SurgeGraph Vertex is an AI writing tool with a mission to help users grow their website traffic through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback